Ongoing Clinical Trials in Neurodegenerative Diseases:
If you or a loved one have been diagnosed with one of the following neurological or neuro-ophthalmic diseases, we invite you to consider participating in one of our clinical studies. Information about our ongoing and planned clinical trials are available below. If you have questions about any of the studies you see listed, please consult with your physician.
Enrollment Complete
The Phase 2 SHINE study recruited 153 individuals (50 to 85 years of age) who have mild-to-moderate Alzheimer’s disease. Participants are randomized to receive either a standard-of-care treatment or the experimental candidate, CT1812 for six months. More information may be found on clinicaltrials.gov under trial identifier NCT03507790.
Actively Recruiting
The Phase 2 SHIMMER study is currently recruiting individuals (50 to 85 years of age) who have mild-to-moderate dementia with Lewy bodies. SHIMMER will enroll up to 120 participants in the United States who will be randomized to receive either a standard-of-care treatment or the experimental candidate, CT1812 for six months. More information may be found at shimmerDLBstudy.com or on clinicaltrials.gov under trial identifier NCT05225415.
Actively Recruiting
The Phase 2 START study is recruiting up to 540 individuals (50 to 85 years of age) in the United States who have early-stage Alzheimer’s disease. Participants will be randomized to receive either a standard-of-care treatment or the experimental candidate, CT1812. The START study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC). More information may be found at start-study.org or on clinicaltrials.gov under trial identifier NCT05531656.
Actively Recruiting
The Phase 2 MAGNIFY study will recruit individuals (≥ 50 years of age) who have a diagnosis of dry age-related macular degeneration with measurable geographic atrophy. MAGNIFY will enroll up to 246 participants who will be randomized to receive either placebo or the experimental candidate, CT1812 for 24 months. More information may be found on clinicaltrials.gov under trial identifier NCT05893537.
Please note: CT1812 is an experimental candidate and has not been approved by the U.S. FDA or other regulatory agency​
Additional Resource for Patients and their Families
Alzheimer's Disease
Dementia with Lewy Bodies
Geographic Atrophy
Clinical Trial Terminology
Before a novel product candidate can be approved, it must complete a rigorous clinical development process, which typically includes three distinct types of trials. Phase 1 clinical trials test experimental treatments at a variety of doses in healthy volunteers to understand how the candidate works in the human body and identify safety issues that may not have been apparent in preclinical research.
Following successful completion of Phase 1 trials, experimental therapies often advance into one or more Phase 2 trials to evaluate the efficacy and safety of a candidate in the target patient population. Goals for Phase 2 trials may include selecting an optimal dose or dosing regimen, identifying specific patient group who may respond to medication more or less favorably, and assessing the safety and tolerability profile. Meetings with the U.S. Food and Drug Administration and other countries’ regulatory authorities are held following the conclusion of Phase 2 clinical trials to review data before proceeding into the next phase of development.
Phase 3 trials are the final step in a product’s clinical develop and are designed to test the optimal dose or dosing regimen in a large number of people with a specific disease or condition. They aim to enroll people with diversity in race, gender, geography, and socioeconomic status to mirror the conditions in which a candidate might be used in the future when it’s broadly available.
Because these studies involve experimental treatments, all clinical trials are closely monitored by regulatory authorities as well as independent ethics committees (IECs) or institutional review boards (IRBs) to ensure that any safety issues that arise are carefully documented.
Expanded Access Policy
We are a clinical stage biopharmaceutical company engaged in the development of small-molecule therapeutics targeting age-related degenerative diseases. We currently have several clinical studies planned or underway that are designed to measure safety and efficacy outcomes of our experimental medications for patients with Alzheimer’s disease, GA secondary to dry age-related macular degeneration and dementia with Lewy bodies.
At this time, we do not offer expanded access to any of our therapies in development. Rather, before our drug candidates complete their clinical development and are reviewed and approved by regulatory authorities, they can only be accessed through participation in our clinical trials.